Influenza roadmap:
Vaccines
Roadmap for the development of candidate vaccines for influenza
Download Influenza-vaccine-development-roadmap2
Naturally attenuated candidates
Next steps
- 1 Vaccine
- 1B Delivery route
Naturally attenuated candidates
Research Question
- Develop safe live virus Influenza vaccines – without risk of reassortment.
- Amenable for mass vaccination – control
Research Gaps and Challenges
- Develop vaccines easy to administer that induce strong mucosal immunity able to block shedding, and prevent infection and transmission of LPAIV and HPAIV
- Regulatory issues regarding attenuated vaccine usage due to safety for public health (possible reversion of virulence)
- Risk of reversion to virulence and/or recombination
- Application may depend on target species swine, equine versus avian species
- Cost of vaccine for each species
Solution Routes
- Solution for blocking reversion of virulence and reassortment
State Of the Art
- No incentive for industry to invest in research on Al attenuated vaccines as current regulation do not allow its use
Projects
What activities are planned or underway?
Risk and economic consequences of contagious animal disease introduction
Planned Completion date 18/10/2024
Source Countries:
Netherlands
Dynamics of sustainability in integrated agriculture : aquaculture systems in the Mekong Delta
Planned Completion date 21/10/2024
Source Countries:
Netherlands